Acuity announces first IND for Wet AMD, ahead of Sirna and the rest of the gang who are going after the same low hanging fruit target (where delivery is easy).
Cheers,
Thomas
Acuity Pharmaceuticals Files First-Ever IND for Therapeutic RNAi
Tuesday August 10, 7:05 am ET
- Milestone Event Moves siRNA toward Human Trials for Treatment of Wet AMD -
PHILADELPHIA, Aug. 10 /PRNewswire/ -- Acuity Pharmaceuticals, a product- focused ophthalmic pharmaceutical company, today announced that it has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) to initiate Phase I clinical trials of Cand5, its lead product candidate for treatment of wet age-related macular degeneration (wet AMD). Cand5 is a small interfering RNA, or siRNA, which uses the powerful mechanism of RNA interference (RNAi) to shut down genes that promote the overgrowth of blood vessels that lead to vision loss in wet AMD, a leading cause of adult blindness that will affect more than two million people in the U.S. by 2010. Acuity is the first to file an IND to take an siRNA therapeutic into clinical trials. |
